Join to View Full Profile
2100 Erwin RdDurham, NC 27705
Phone+1 919-684-8964
Fax+1 919-684-5325
Dr. Lanasa is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Duke University HospitalFellowship, Hematology and Medical Oncology, 2005 - 2008- Duke University HospitalResidency, Internal Medicine, 2002 - 2005
University of Pittsburgh School of MedicineClass of 2002
Certifications & Licensure
MD State Medical License 2017 - 2019
NC State Medical License 2005 - 2014
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia Start of enrollment: 2007 May 10
- Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM Start of enrollment: 2008 Jun 19
- Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2010 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- 16 citationsNatural history of monoclonal B-cell lymphocytosis among relatives in CLL families.Susan L. Slager, Mark C. Lanasa, Gerald E. Marti, Sara J. Achenbach, Nicola J. Camp
Blood. 2021-04-15 - 60 citationsPhase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200Daruka Mahadevan, Mark C. Lanasa, Charles M. Farber, Manjari Pandey, Maria Whelden
Journal for Immunotherapy of Cancer. 2019-08-23 - 73 citationsActionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL.Alexandra Schrader, Giuliano Crispatzu, Sebastian Oberbeck, Petra Mayer, S. Pützer
Nature Communications. 2018-02-15
Press Mentions
BeiGene Abandons Ociperlimab over Poor Phase 3 Prospects in Latest Blow to TIGITsApril 3rd, 2025- BeiGene Discontinues Lung Cancer Drug Study After Interim Data Showed Limited Survival BenefitApril 3rd, 2025
- BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung CancerMarch 31st, 2025
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
